FDA’s Q&A for Safety Reporting Requirements for IND and IND-exempt BA/BE Studies

Welcome back! When a person in a clinical study experiences a serious medical problem, speed and accuracy matters. On October 19, 2026, the U.S. Food and Drug Administration’s (FDA) Small Entity Compliance Guide “Safety Reporting Requirements for INDs and BA/BE Studies” [1] was released. It provides some Questions and Answers (Q&A) on how sponsors and investigators should identify, evaluate, and report important safety information for investigational new drug (IND) studies and certain bioavailability and bioequivalence (BA/BE) studies. This guidance follows in tandem with FDA’s guidance, “Investigator Responsibilities – Safety Reporting for Investigational Drugs and Devices (December 2025)” [2] .

This overview focuses on the practical question: What should an establishment do to make sure a meaningful safety signal reaches the FDA without flooding the system with reports that do not meet the reporting standard?

The basic idea is straightforward: a sponsor must promptly report certain serious and unexpected suspected adverse reactions. Each word matters. A healthy event generally needs to be serious, not reasonably expected based on existing information, and supported by evidence suggesting a reasonable possibility that the drug caused it.

Some key reporting timelines for consideration:

  • 15 calendar day reports: certain serious and unexpected suspected adverse reactions generally require prompt reporting within 15 calendar days after the sponsor determines the information qualifies.

  • 7 calendar day reports: unexpected fatal or life-threatening suspected adverse reactions generally require faster reporting.

  • Follow-up information: relevant new details should be submitted promptly after the initial report.

The reporting clock and exact submission pathway depend on the applicable regulation and facts. Establishments should use current FDA regulations, forms, electronic submission instructions, and study-specific procedures.

IND safety reporting usually centers on the sponsor’s evaluation of serious, unexpected suspected adverse reactions and other important findings that may suggest a significant risk. BA/BE studies conducted in humans can also trigger safety reporting duties, including studies that may not operate under an IND. The responsible organization must first determine which regulatory framework applies to each study and document that decision. The guide is relevant to small drug and biologics companies, IND sponsors, sponsor-investigators, contract research organizations, clinical research sites, safety vendors, and organizations conducting human BA/BE studies. Even when work is outsourced, the sponsor should understand which duties remain with it and maintain effective oversight.

Considerations for establishments:

  • Who owns the decision? The person or committee authorized to decide whether an event is reportable should be determined.

  • Where does the information enter? Mapping reports from sites, laboratories, medical monitors, vendors, literature surveillance, and other studies involving the product should be performed.

  • Can related cases be reviewed together? A single case may look unrelated, while several similar cases may reveal a pattern.

  • Are expectations/predictability assessed consistently? Establishments should use the correct safety information and control its versions.

  • Are roles clear? Agreements with investigators, CROs, safety vendors, and partners should define notification deadlines, data fields, follow up duties, and escalation routes.

  • Can the organization prove what happened? Clear audit trail of receipt, medical review, causality assessment, reporting decisions, submissions, and follow up should be kept.

Some risks for consideration:

  • Missing or delaying a true safety signal: late intake, unclear ownership, or incomplete escalation can delay a required report. Participant and investigators may not receive information needed to make safe decisions. Regulatory consequences may follow due to this.

  • Safety evidence often sits in separate systems or with different vendors. If teams cannot connect similar events across sites or studies, they may miss a reportable pattern. Reconciliations between clinical, safety, laboratory, and partner records are therefore essential.

  • Different reviewers may reach different conclusions where definitions, reference documents, and escalation thresholds are vague. This creates uneven reporting and weakens the organization’s ability to defend its decisions.

The bottom line is that good safety reporting is not simply a race to submit every serious event. It’s a controlled process for finding credible signs of drug related harm, acting within the required timeline, and preserving enough evidence to explain the decision later. Smaller organizations can meet that standard by clarifying ownership, connecting their information, building time into internal workflows, and testing the system before a real emergency exposes its weak points.

Thanks for stopping by! Keep checking back as we continue following industry trends!

Have questions? Contact us here!

Reference

[1] https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-reporting-requirements-inds-and-babe-studies?utm_medium=email&utm_source=govdelivery

[2] https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigator-responsibilities-safety-reporting-investigational-drugs-and-devices

Next
Next

A Recall to Action: What Regulated Companies Need to Know